Atm CRISPR Activation Plasmid (h): sc-400192-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Atm CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- Atm CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by Atm CRISPR Activation Plasmid (h) and Atm CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the ATM transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Atm Antibody (G-12): sc-377293
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Atm CRISPR Activation Plasmid (h) | sc-400192-ACT | 20 µg | $397.00 |
ATM encodes the serine/threonine kinase Atm, a central regulator of the DNA damage response that is rapidly activated by DNA double-strand breaks. Upon activation, Atm coordinates checkpoint control and DNA repair by phosphorylating key substrates across homologous recombination, cell-cycle arrest, and apoptosis pathways, including signaling through p53 and CHK2. ATM function is integrated with chromatin remodeling and replication stress responses to preserve genome stability. Dysregulation of ATM signaling is linked to genomic instability phenotypes and is frequently studied in the context of cancer biology and inherited DNA repair disorders.
Atm CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous ATM expression without altering the underlying DNA sequence.
Atm CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the ATM locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the ATM transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous Atm expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native ATM locus and enabling the study of Atm-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of Atm pathway restoration in tumor cells with silenced or reduced ATM expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.